

Nick Pavlakis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3227622/publications.pdf>

Version: 2024-02-01

151
papers

4,815
citations

159585

30
h-index

110387

64
g-index

153
all docs

153
docs citations

153
times ranked

7908
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Safety and activity of microRNA-loaded micicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. <i>Lancet Oncology</i> , The, 2017, 18, 1386-1396. | 10.7 | 508 |
| 2 | Ado-Trastuzumab Emtansine for Patients With <i>HER2</i> -Mutant Lung Cancers: Results From a Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2532-2537. | 1.6 | 381 |
| 3 | Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1233-1243. | 1.1 | 324 |
| 4 | Impact of Specific Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations and Clinical Characteristics on Outcomes After Treatment With <i>EGFR</i> Tyrosine Kinase Inhibitors Versus Chemotherapy in <i>EGFR</i> -Mutant Lung Cancer: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1958-1965. | 1.6 | 280 |
| 5 | Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2029-2037. | 7.0 | 209 |
| 6 | Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. <i>Theranostics</i> , 2017, 7, 1149-1158. | 10.0 | 201 |
| 7 | Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2728-2735. | 1.6 | 183 |
| 8 | Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2012, 20, 1235-1242. | 2.2 | 179 |
| 9 | Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. <i>Epigenomics</i> , 2016, 8, 1079-1085. | 2.1 | 176 |
| 10 | Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naïve patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 569-580. | 10.7 | 117 |
| 11 | Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. <i>Lancet Oncology</i> , The, 2020, 21, 1213-1223. | 10.7 | 109 |
| 12 | Bisphosphonates and other bone agents for breast cancer. , 2012, , CD003474. | | 98 |
| 13 | Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1784-1791. | 1.1 | 75 |
| 14 | Afatinib in patients with metastatic or recurrent <i>HER2</i> -mutant lung cancers: a retrospective international multicentre study. <i>European Journal of Cancer</i> , 2019, 109, 28-35. | 2.8 | 69 |
| 15 | Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2018, 4, 1597. | 7.1 | 68 |
| 16 | Targeting BRAF mutations in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 1119-1124. | 2.8 | 65 |
| 17 | Evolving role of regorafenib for the treatment of advanced cancers. <i>Cancer Treatment Reviews</i> , 2020, 86, 101993. | 7.7 | 61 |
| 18 | Ranpirnase – an antitumour ribonuclease: its potential role in malignant mesothelioma. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 391-399. | 3.1 | 60 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors. <i>Medicine (United States)</i> , 2015, 94, e1281. | 1.0 | 56 |
| 20 | Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2020, 16, 467-482. | 2.9 | 56 |
| 21 | Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2258-2264. | 1.6 | 52 |
| 22 | Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. <i>Histopathology</i> , 2017, 70, 402-411. | 2.9 | 52 |
| 23 | A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. <i>Lung Cancer</i> , 2013, 81, 422-427. | 2.0 | 51 |
| 24 | Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice. <i>Journal of Clinical Medicine</i> , 2014, 3, 1-24. | 2.4 | 51 |
| 25 | Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis. <i>EJNMMI Research</i> , 2017, 7, 46. | 2.5 | 45 |
| 26 | Targeted therapy for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 991-1006. | 2.4 | 44 |
| 27 | Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. <i>British Journal of Cancer</i> , 2016, 114, 505-509. | 6.4 | 43 |
| 28 | Prognostic and predictive biomarkers in neuroendocrine tumours. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 268-282. | 4.4 | 42 |
| 29 | Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. <i>Clinical Therapeutics</i> , 2017, 39, 2158-2168. | 2.5 | 38 |
| 30 | Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?. , 2021, 9, e002248. | | 35 |
| 31 | HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. <i>Lung Cancer</i> , 2015, 90, 617-619. | 2.0 | 34 |
| 32 | Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?. <i>Cancers</i> , 2020, 12, 1341. | 3.7 | 34 |
| 33 | Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. <i>Endocrine</i> , 2017, 57, 366-375. | 2.3 | 33 |
| 34 | Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma. <i>Neoplasia</i> , 2016, 18, 425-435. | 5.3 | 30 |
| 35 | Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 138, 79-87. | 2.0 | 29 |
| 36 | The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?. <i>Cancers</i> , 2021, 13, 4824. | 3.7 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Lost in translation: returning germline genetic results in genome-scale cancer research. <i>Genome Medicine</i> , 2017, 9, 41. | 8.2 | 27 |
| 38 | A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 142, 34-40. | 2.0 | 27 |
| 39 | Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions. <i>Cancer Treatment Reviews</i> , 2018, 66, 1-6. | 7.7 | 26 |
| 40 | Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1278-1284. | 5.0 | 25 |
| 41 | Challenges in chemotherapy delivery: comparison of standard chemotherapy delivery to locoregional vascular mass fluid transfer. <i>Future Oncology</i> , 2018, 14, 647-663. | 2.4 | 23 |
| 42 | EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e859-e869. | 2.6 | 23 |
| 43 | Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. <i>PLoS ONE</i> , 2015, 10, e0135599. | 2.5 | 22 |
| 44 | Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). <i>PLoS ONE</i> , 2016, 11, e0158140. | 2.5 | 22 |
| 45 | Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 218-224. | 1.0 | 22 |
| 46 | Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 237. | 2.8 | 22 |
| 47 | Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. <i>Scientific Reports</i> , 2014, 4, 6152. | 3.3 | 20 |
| 48 | A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2016, 114, 524-531. | 6.4 | 20 |
| 49 | New drug developments in metastatic gastric cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481880807. | 3.2 | 19 |
| 50 | High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2020, 110, 950-958. | 2.5 | 19 |
| 51 | Immune Checkpoint Inhibitors for Brain Metastases. <i>Current Oncology Reports</i> , 2017, 19, 38. | 4.0 | 18 |
| 52 | Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0191455. | 2.5 | 18 |
| 53 | Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. <i>ESMO Open</i> , 2020, 5, e001090. | 4.5 | 18 |
| 54 | Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2021, 155, 28-33. | 2.0 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Histopathological tumour viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data. ANZ Journal of Surgery, 2018, 88, E167-E172. | 0.7 | 16 |
| 56 | Equivocal ALK fluorescence in situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing. Histopathology, 2015, 67, 654-663. | 2.9 | 15 |
| 57 | ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer, 2016, 16, 339. | 2.6 | 15 |
| 58 | Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review. Frontiers in Oncology, 2021, 11, 706331. | 2.8 | 15 |
| 59 | A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. American Journal of Surgical Pathology, 2021, 45, 394-404. | 3.7 | 15 |
| 60 | Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management*. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 167-176. | 1.1 | 14 |
| 61 | Malignant Cardiac Tamponade from Non-Small Cell Lung Cancer: Case Series from the Era of Molecular Targeted Therapy. Journal of Clinical Medicine, 2015, 4, 75-84. | 2.4 | 14 |
| 62 | Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations. Immunotherapy, 2021, 13, 941-952. | 2.0 | 14 |
| 63 | The role of proteomics in the age of immunotherapies. Mammalian Genome, 2018, 29, 757-769. | 2.2 | 12 |
| 64 | Localized malignant pleural mesothelioma with renal metastasis. Oxford Medical Case Reports, 2015, 2015, 170-172. | 0.4 | 11 |
| 65 | The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Lung Cancer, 2016, 102, 21-27. | 2.0 | 11 |
| 66 | The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0172307. | 2.5 | 11 |
| 67 | The Economic Impact on Australian Patients with Neuroendocrine Tumours. Patient, 2020, 13, 363-373. | 2.7 | 11 |
| 68 | INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG) – Final overall and subgroup results. Journal of Clinical Oncology, 2015, 33, 4003-4003. | 1.6 | 11 |
| 69 | Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report. Molecular and Clinical Oncology, 2015, 3, 817-819. | 1.0 | 10 |
| 70 | Factors Affecting Whether Or Not Cancer Patients Consider Using Acupuncture. Acupuncture in Medicine, 2017, 35, 107-113. | 1.0 | 10 |
| 71 | Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS). Neuroendocrinology, 2018, 107, 32-41. | 2.5 | 10 |
| 72 | Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. Future Oncology, 2019, 15, 1363-1383. | 2.4 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 704-715. | 4.1 | 10 |
| 74 | Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2015, 3, 107-15. | 0.1 | 10 |
| 75 | Acupuncture in Oncology: The Effectiveness of Acupuncture May Not Depend on Needle Retention Duration. <i>Integrative Cancer Therapies</i> , 2018, 17, 458-466. | 2.0 | 9 |
| 76 | Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, 313-319. | 2.3 | 9 |
| 77 | Mass Cytometry Reveals a Sustained Reduction in CD16+ Natural Killer Cells Following Chemotherapy in Colorectal Cancer Patients. <i>Frontiers in Immunology</i> , 2019, 10, 2584. | 4.8 | 9 |
| 78 | Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 620. | 3.7 | 9 |
| 79 | Accuracy and Prognostic Significance of Oncologists'™ Estimates and Scenarios for Survival Time in Advanced Gastric Cancer. <i>Oncologist</i> , 2019, 24, e1102-e1107. | 3.7 | 9 |
| 80 | Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2020, 49, 224-229. | 1.1 | 9 |
| 81 | Convergent priorities and tensions: a qualitative study of the integration of complementary and alternative therapies with conventional cancer treatment. <i>Supportive Care in Cancer</i> , 2018, 26, 1791-1797. | 2.2 | 8 |
| 82 | Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 256-263. | 1.1 | 8 |
| 83 | Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity. <i>Journal of Surgical Research</i> , 2018, 227, 158-167. | 1.6 | 8 |
| 84 | ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses. <i>Clinical Lung Cancer</i> , 2018, 19, 457-459. | 2.6 | 8 |
| 85 | Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. <i>Pathology</i> , 2019, 51, 673-680. | 0.6 | 8 |
| 86 | Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition. <i>Annals of Translational Medicine</i> , 2020, 8, 555-555. | 1.7 | 8 |
| 87 | ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. <i>Oncologist</i> , 2020, 25, 641-649. | 3.7 | 8 |
| 88 | Computed tomography (CT)-defined sarcopenia and myosteatosis are prevalent in patients with neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT). <i>European Journal of Clinical Nutrition</i> , 2022, 76, 143-149. | 2.9 | 8 |
| 89 | Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2543-2550. | 1.0 | 8 |
| 90 | Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100075. | 1.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours. <i>Oncotarget</i> , 2020, 11, 2636-2646. | 1.8 | 8 |
| 92 | Diagnostic Accuracy of Imaging Modalities in the Evaluation of Vascular Invasion in Pancreatic Adenocarcinoma: A Meta-Analysis. <i>World Journal of Oncology</i> , 2013, 4, 74-82. | 1.5 | 8 |
| 93 | An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma. <i>Lung Cancer: Targets and Therapy</i> , 2022, Volume 13, 1-12. | 2.7 | 7 |
| 94 | Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration. <i>Journal of Global Oncology</i> , 2017, 3, 380-388. | 0.5 | 6 |
| 95 | Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 339-349. | 2.4 | 6 |
| 96 | Pattern of care and survival of anaplastic lymphoma kinase rearranged non-ALK+ small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e275-e282. | 1.1 | 6 |
| 97 | Accreditation Standard Guideline Initiative for Tai Chi and Qigong Instructors and Training Institutions. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 51. | 1.4 | 6 |
| 98 | Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1539-1542. | 1.0 | 6 |
| 99 | Lung cancer treatment patterns and factors relating to systemic therapy use in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, . | 1.1 | 6 |
| 100 | Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9105-TPS9105. | 1.6 | 6 |
| 101 | Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2700. | 2.4 | 5 |
| 102 | Safety and Feasibility of Repeatable Hepatic Vascular Isolation Chemotherapy: A Pilot Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 3699-3708. | 1.5 | 4 |
| 103 | Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care. <i>Journal of Clinical Medicine</i> , 2019, 8, 1455. | 2.4 | 4 |
| 104 | Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 251-270. | 2.4 | 4 |
| 105 | Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 526-539. | 1.1 | 4 |
| 106 | The evolving landscape of treatment for advanced gastric cancer and the role of anti-angiogenic therapy: implications from results of the INTEGRATE study. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 29-29. | 3.0 | 3 |
| 107 | Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e45-e49. | 1.1 | 3 |
| 108 | Emerging biological therapies for the treatment of malignant pleural mesothelioma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 179-192. | 2.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Final results of AGITG ATTAX3 study: Randomized phase II study of weekly docetaxel (T), cisplatin, and fluoropyrimidine (F) with or without panitumumab (P) in advanced esophagogastric (OG) cancer.. Journal of Clinical Oncology, 2013, 31, 4081-4081. | 1.6 | 3 |
| 110 | INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)â€”A study by the Australasian Gastrointestinal Trials Group (AGITG).. Journal of Clinical Oncology, 2013, 31, TPS4157-TPS4157. | 1.6 | 3 |
| 111 | Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. JMIR Research Protocols, 2019, 8, e14361. | 1.0 | 3 |
| 112 | EPID-13. ANTI-ANGIOGENIC THERAPY FOR HIGH-GRADE GLIOMA: A META-ANALYSIS. Neuro-Oncology, 2018, 20, vi82-vi83. | 1.2 | 2 |
| 113 | The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (¹⁸F) positronâ€”emission tomography positive intermediate grade pancreatic neuroendocrine tumors. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 150-157. | 1.1 | 2 |
| 114 | BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17.. Journal of Clinical Oncology, 2012, 30, 3515-3515. | 1.6 | 2 |
| 115 | ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation.. Journal of Clinical Oncology, 2013, 31, TPS3649-TPS3649. | 1.6 | 2 |
| 116 | Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal cancer (mCRC): A meta-analysis.. Journal of Clinical Oncology, 2014, 32, 3552-3552. | 1.6 | 2 |
| 117 | Life-threatening diarrhea in neuroendocrine tumors: two case reports. Journal of Medical Case Reports, 2021, 15, 542. | 0.8 | 2 |
| 118 | INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).. Journal of Clinical Oncology, 2022, 40, TPS366-TPS366. | 1.6 | 2 |
| 119 | The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. Targeted Oncology, 2022, 17, 95. | 3.6 | 2 |
| 120 | Cardiac toxicity from sunitinib: Do we need to be more vigilant?. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 217-218. | 1.1 | 1 |
| 121 | Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 3-12. | 1.1 | 1 |
| 122 | The unmet supportive care needs, quality of life, and care experiences of patients with functioning and non-functioning Neuroendocrine tumours (NETs) at early diagnosis. Patient Education and Counseling, 2021, 105, 212-220. | 2.2 | 1 |
| 123 | The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2013, 31, e22175-e22175. | 1.6 | 1 |
| 124 | Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study.. Journal of Clinical Oncology, 2014, 32, TPS7612-TPS7612. | 1.6 | 1 |
| 125 | Meta-analysis of outcomes of VEGF and EGFR targeted biologic therapy in relapsed metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 534-534. | 1.6 | 1 |
| 126 | Preliminary direct evidence of a dose-response relationship for [Y-90]-microsphere selective internal radionuclide therapy (SIRT) in hepatic malignancy.. Journal of Clinical Oncology, 2015, 33, 11064-11064. | 1.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Antiangiogenic agents (AAs) in metastatic oesophago-gastric cancer (mOGC): A systematic review and meta-analysis.. Journal of Clinical Oncology, 2015, 33, e15111-e15111. | 1.6 | 1 |
| 128 | Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers. Asia-Pacific Journal of Clinical Oncology, 2022, , . | 1.1 | 1 |
| 129 | Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases. Annals of Surgical Oncology, 2022, 29, 3387-3389. | 1.5 | 1 |
| 130 | Anti-angiogenic therapy for lung cancer. The Cochrane Library, 0, , . | 2.8 | 0 |
| 131 | Phase III trials of neo-adjuvant chemotherapy in Stage IIIA non-small cell lung cancer “ does size matter?. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 73-75. | 1.1 | 0 |
| 132 | Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction. Oxford Medical Case Reports, 2014, 2014, 105-106. | 0.4 | 0 |
| 133 | Dramatic response to selective internal radiation therapy for unresectable hepatocellular carcinoma. Oxford Medical Case Reports, 2015, 2015, 194-195. | 0.4 | 0 |
| 134 | Adjuvant anti-VEGF therapy for overall survival and relapse-free survival in patients with resected non-metastatic colorectal cancer. The Cochrane Library, 0, , . | 2.8 | 0 |
| 135 | Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2020, 20, 305-324. | 2.4 | 0 |
| 136 | Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series. Asia-Pacific Journal of Clinical Oncology, 2021, , . | 1.1 | 0 |
| 137 | Immunotherapy in Non-“Small-Cell Lung Cancer: Hallelujah!”But Salvation Is Still Awaited by Many. JCO Oncology Practice, 2021, 17, OP.21.00506. | 2.9 | 0 |
| 138 | Phase II trial of BNC105P as second-line chemotherapy for advanced malignant pleural mesothelioma (MPM): Australasian Lung Cancer Trials Group and NHMRC Clinical Trials Centre Collaboration.. Journal of Clinical Oncology, 2012, 30, 7079-7079. | 1.6 | 0 |
| 139 | A mapping algorithm of health preferences from EORTC QLQ C30 to health utility index mark 3 (HUI3) in advanced colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 547-547. | 1.6 | 0 |
| 140 | EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901).. Journal of Clinical Oncology, 2014, 32, 438-438. | 1.6 | 0 |
| 141 | Circulating microRNAs associated with docetaxel-resistant castration resistant prostate cancer.. Journal of Clinical Oncology, 2014, 32, 44-44. | 1.6 | 0 |
| 142 | Old and new prognostic factors in a series of 910 patients with malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2014, 32, 7586-7586. | 1.6 | 0 |
| 143 | Neutrophil/lymphocyte ratio (NLR) and FDG PET as predictive measures of response and prognosis in patients treated with Y-90 microsphere selective internal radionuclide therapy (SIRT).. Journal of Clinical Oncology, 2015, 33, e22137-e22137. | 1.6 | 0 |
| 144 | Adjuvant therapy in pancreatic adenocarcinoma: A systemic review and meta-analysis.. Journal of Clinical Oncology, 2016, 34, 330-330. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Clinical utilization of targetable molecular results in pancreatic cancer: Longer-term outcomes from the Individualized Molecular Pancreatic Cancer Therapy (IMPACT) trial.. Journal of Clinical Oncology, 2017, 35, 314-314. | 1.6 | 0 |
| 146 | Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high-volume referral centre.. Journal of Clinical Oncology, 2017, 35, 395-395. | 1.6 | 0 |
| 147 | As cancer therapy becomes more complex, we must enhance our professional standards. Journal of Pharmacy Practice and Research, 2020, 50, 461-465. | 0.8 | 0 |
| 148 | Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2022, 22, 39-51. | 2.4 | 0 |
| 149 | 341â€¦A phase Ib expansion cohort of pixatimod plus nivolumab in previously treated, microsatellite stable metastatic colorectal cancer (MSS mCRC). , 2021, 9, A367-A367. | | 0 |
| 150 | 340â€¦A phase Ib study of the safety and tolerability of pixatimod plus nivolumab in subjects with advanced solid tumors with an expansion cohort in metastatic pancreatic adenocarcinoma (mPDAC). , 2021, 9, A366-A366. | | 0 |
| 151 | PEARL: A randomised phase 3 trial of palliative care early in advanced lung cancers (ALTG/TOGA 13/008).. Journal of Clinical Oncology, 2022, 40, 12020-12020. | 1.6 | 0 |